|
Real-time Estimate
Cboe BZX
23:15:00 06/11/2026 +04
|
5-day change | 1st Jan Change | ||
| 6.620 USD | +2.95% |
|
-4.23% | -45.02% |
| 10-24 | Ocular Therapeutix, Inc. - Special Call | |
| 10-20 | Ocular Therapeutix Has 75% Success Probability for Axpaxli in Wet Age-Related Macular Degeneration, UBS Says | MT |
Company Valuation: Ocular Therapeutix, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 534 | 216.4 | 491.6 | 1,343 | 2,586 | 1,412 | - | - |
| Change | - | -59.47% | 127.16% | 173.13% | 92.64% | -45.4% | - | - |
| Enterprise Value (EV) 1 | 421.2 | 168.1 | 491.6 | 1,019 | 2,586 | 987 | 1,187 | 1,131 |
| Change | - | -60.09% | 192.42% | 107.3% | 153.81% | -61.84% | 20.3% | -4.73% |
| P/E | -77.4x | -2.9x | -4.42x | -7x | -8.55x | -4.31x | -4.55x | -6.02x |
| PBR | - | - | - | - | - | 3.73x | 4.68x | 3.9x |
| PEG | - | -0x | -1.07x | -0.3x | -0.5x | -0.85x | 0.86x | 0.2x |
| Capitalization / Revenue | 12.3x | 4.2x | 8.41x | 21.1x | 49.8x | 26.7x | 13.8x | 5.09x |
| EV / Revenue | 9.68x | 3.26x | 8.41x | 16x | 49.8x | 18.7x | 11.6x | 4.08x |
| EV / EBITDA | -5.57x | -2.2x | -6.19x | -6.07x | -9.73x | -3.27x | -3.38x | -3.84x |
| EV / EBIT | -5.4x | -2.14x | -5.97x | -5.93x | -9.58x | -2.85x | -3.5x | -4.03x |
| EV / FCF | -6.31x | -2.65x | -6.44x | -7.49x | -11.9x | -3.54x | -5.07x | -27.6x |
| FCF Yield | -15.8% | -37.7% | -15.5% | -13.3% | -8.39% | -28.3% | -19.7% | -3.62% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.09 | -0.97 | -1.01 | -1.22 | -1.42 | -1.492 | -1.413 | -1.068 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 43.52 | 51.49 | 58.44 | 63.72 | 51.95 | 52.84 | 102 | 277.4 |
| EBITDA 1 | -75.62 | -76.54 | -79.4 | -168 | -265.7 | -301.7 | -351.7 | -294.9 |
| EBIT 1 | -78.04 | -78.65 | -82.38 | -171.8 | -270 | -346.4 | -339.2 | -280.8 |
| Net income 1 | -6.553 | -71.04 | -80.74 | -193.5 | -265.9 | -334.2 | -330.4 | -275.7 |
| Net Debt 1 | -112.7 | -48.29 | - | -323.6 | - | -425.1 | -224.7 | -280.9 |
| Reference price 2 | 6.970 | 2.810 | 4.460 | 8.540 | 12.140 | 6.430 | 6.430 | 6.430 |
| Nbr of stocks (in thousands) | 76,610 | 77,010 | 110,219 | 157,217 | 213,047 | 219,616 | - | - |
| Announcement Date | 28/02/22 | 06/03/23 | 11/03/24 | 03/03/25 | 05/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.31x | 18.68x | -3.27x | -.--% | 1.41B | |
| 39.94x | 13.51x | 30.01x | 0.5% | 1,216B | |
| 39.86x | 6.69x | 18.83x | 1.96% | 656B | |
| 37.08x | 8.43x | 17.39x | 2.4% | 509B | |
| 21.12x | 5.13x | 12.77x | 2.56% | 384B | |
| 97.32x | 5.95x | 25.36x | 2.32% | 362B | |
| 23.5x | 6.02x | 14.53x | 2.65% | 311B | |
| 24.85x | 4.96x | 13.98x | 1.76% | 293B | |
| 28.41x | 7.33x | 12.69x | 2.19% | 249B | |
| -40.11x | 7.32x | 45.99x | 1.97% | 208B | |
| Average | 26.77x | 8.40x | 18.83x | 1.83% | 418.92B | |
| Weighted average by Cap. | 35.87x | 8.58x | 22.22x | 1.73% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- OCUL Stock
- Valuation Ocular Therapeutix, Inc.
Select your edition
All financial news and data tailored to specific country editions
